Company Profile

In November 2006 Tanox, Inc. was acquired by Genentech - the first acqusiirton by Genentech in its thiry year history. Tanox, Inc. discovers and develops therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system. The Company's products are genetically engineered antibodies that target a specific molecule (antigen). Tanox has discovered a novel approach for treating allergies and asthma by using anti-immunoglobulin E (anti-IgE) antibodies capable of blocking IgE, a causative agent of the allergy pathway, thus preventing the onset of disease symptoms